Drug profile · INN
cenobamate
ONTOZRY
cenobamate (ONTOZRY) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: oral. Current US regulatory status: approved.
Drug details — cenobamate
- US status
- approved
- Class
- Nervous system (N03)
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
cenobamate (ONTOZRY) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
GABA-A receptor; anion channel positive allosteric modulator
Primary target: GABA-A receptor; anion channel
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is cenobamate?
cenobamate (ONTOZRY) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for cenobamate?
ONTOZRY is a marketed brand name for cenobamate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cenobamate?
cenobamate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.